Stereotactic Body Radiation Therapy and Abiraterone Acetate for Patients Affected by Oligometastatic Castrate-Resistant Prostate Cancer: A Randomized Phase II Trial (ARTO).

Giulio Francolini Andrea Gaetano AllegraBeatrice DettiVanessa Di CataldoSaverio CainiAlessio Bruni Gianluca IngrossoRolando Maria D'AngelilloAnna Rita AlittoMatteo AugugliaroLuca TriggianiSilvana ParisiGaetano FacchiniMarco BaniniGabriele Simontacchi Isacco Desideri Icro MeattiniRichard K ValicentiLorenzo Livinull null

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)

The trial reached its primary end point of biochemical control and PFS, suggesting a clinical advantage for SBRT in addition to first-line AAP treatment in patients with metastatic castration-resistant prostate cancer.

Keyphrases

radiation therapy
prostate cancer
end stage renal disease
ejection fraction
chronic kidney disease
clinical trial
peritoneal dialysis
prognostic factors
radical prostatectomy
study protocol
randomized controlled trial
open label
locally advanced
combination therapy